Table 2.
Adherence to PMTCT guidelines, stratified by ART eligibility
| All women | CD4 ≤ 350 | CD4 > 350 | |
|---|---|---|---|
| 158 | 72 | 67 | |
| 1. First ANC visit prior to 20 weeks gestation | |||
| No record of gestational age, last menstrual period, or expected date of delivery | 8 (5%) | 4 (6%) | 4 (6%) |
| <20 weeks gestation at first ANC | 39 (26%) | 15 (21%) | 20 (30%) |
| 2. Initiate CD4 testing at first ANC visit | |||
| CD4 tests results from first ANC found | 139 (88%) | 72 | 67 |
| WHO clinical stage found | 86 (54%) | 43 (60%) | 32 (48%) |
| 3. Initiate AZT prophylaxis when first eligible (at least 14 weeks gestation and Hb ≥ 8 g/dl) | |||
| >13 weeks gestation at first visit | 141 (89%) | 65 (90%) | 58 (87%) |
| Hb ≥ 8 g/dl at first visit | 132 (84%) | 56 (78%) | 60 (90%) |
| Known eligible for AZT | 118 (75%) | 51 (72%) | 52 (78%) |
| Received AZT at first visit, if eligible | 81 (69%) | 37 (73%) | 32 (62%) |
| 4. Receive CD4 count results | |||
| Have CD4 results visit recorded | 53 (38%) | 36 (50%) | 17 (25%) |
| Made a return visit to clinic <3 weeks | 38 (24%) | 24 (33%) | 13 (19%) |
| Made a return visit to within 60 days | 96 (69%) | 47 (65%) | 49 (73%) |
| Median days to CD4 results received (n = 106) | 28 (IQR: 8–34) | 19 (IQR: 8–29) | 29 (IQR: 8–36) |
| 5. Initiate ART within 30 days of first ANC or receive 60-day uninterrupted supply of AZT | |||
| Initiate ART within 30 days of first ANC | N/A/1 | 2 (3%) | N/A |
| Initiated ART within 60 days of first ANC | N/A | 15 (21%) | N/A |
| Median days to ART initiation (n = 15) | N/A | 47 (IQR: 37–57) | N/A |
| Weeks gestation at ART initiation (n = 15) | N/A | 27 (IQR: 24–33) | N/A |
| Receive 60-day uninterrupted supply of AZT | N/A | N/A | 10 (15%) |
| Received 60-day supply of AZT within 60 days | N/A | N/A | 20 (30%) |
| Median days from first AZT to 2nd AZT (n = 20) | N/A | N/A | 31 (IQR: 29–36) |
/1 N/A = not applicable.